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Abstract 
Motivation: Untargeted metabolomics comprehensively characterizes small molecules and elucidates 
activities of biochemical pathways within a biological sample. Despite computational advances, inter-
preting collected measurements and determining their biological role remains a challenge. 
Results: To interpret measurements, we present an inference-based approach, termed Probabilistic 
modeling for Untargeted Metabolomics Analysis (PUMA). Our approach captures measurements and 
known information about the sample under study in a generative model and uses stochastic sampling 
to compute posterior probability distributions. PUMA predicts the likelihood of pathways being active, 
and then derives a probabilistic annotation, which assigns chemical identities to the measurements. 
PUMA is validated on synthetic datasets. When applied to test cases, the resulting pathway activities 
are biologically meaningful and distinctly different from those obtained using statistical pathway enrich-
ment techniques. Annotation results are in agreement to those obtained using other tools that utilize 
additional information in the form of spectral signatures. Importantly, PUMA annotates many additional 
measurements.  
Availability: The code and datasets are on https://github.com/HassounLab/PUMA 
Contact: soha@cs.tufts.edu  
Supplementary information: Supplementary data are available at Bioinformatics online. 
 
 
1 Introduction  
Analyzing cellular responses to perturbations such as drug treatments 
and genetic modifications promises to elucidate cellular metabolism, lead-
ing to improved outcomes in personalized medicine and synthetic biology. 
Metabolomics has emerged as the new ‘omics’, providing a read out of 
cellular activity that is most predictive of phenotype. Metabolomics so far 
have played a critical role in advancing applications spanning biomarker 
discovery (1), drug discovery and development, (2), plant biology (3), nu-
trition (4) and environmental health (5). Importantly, the advent of untar-
geted metabolomics to measure molecular masses and spectral signatures 
of thousands of small molecule metabolites for a biological sample allows 
unprecedented opportunities to characterize the phenotype.  
The success of untargeted metabolomics in providing insight into cel-
lular behavior however hinges on solving two problems. Metabolite anno-
tation, concerns associating measured masses with their chemical identi-
ties. This problem is challenging, as a particular mass may be associated 
with multiple chemical formulas (e.g., there are 21,988 known molecular 
formulas associated with C20H24N2O3). There are several techniques for 
annotating measurements. Database lookups rely on comparing the meas-
ured spectral signature against experimentally generated fragmentation 
patterns cataloged in reference spectral databases (e.g., METLIN (6), 
HMDB (7), MassBank (8), NIST (9)). Database coverage however is lim-
ited as catalogued spectral signatures are obtained experimentally. Alter-
natively, computational methods that either mimic the ionization and frag-
mentation process or utilize machine learning techniques (e.g., MetFrag 
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(10), Fragment Identificator (FiD) (11), CFM-ID (12), CSI:FingerID (13)) 
score the measured spectra against the predicted spectra of molecules in a 
candidate set. The chemical identity associated with the highest scoring 
signature(s) is then assigned to the measured spectra. Other annotation 
techniques exploit the biological context of the measurements. iMet(14) 
and BioCAN (15) exploit data about local neighborhoods within the net-
work graphs to improve annotation.  
The second problem, pathway enrichment analysis, concerns interpret-
ing measurements within their biological context to study coordinated 
changes arising in response to cellular perturbations. Overrepresentation 
Analysis (ORA) tools (e.g., MESA (16), MetaboAnalyst (17), MPEA 
(18))  employ statistical testing (e.g., Fisher’s exact test) to determine if a 
pathway is enriched in measured metabolites to a degree different than 
expected by chance when compared to other cellular pathways or those in 
a reference sample (19). Pathway enrichment techniques can be broadly 
classified in two categories. Topological Analysis (TA) compute the ob-
served metabolites’ centrality and connectivity, metrics that reflect the im-
portance of a metabolite in the turnover of molecules through a pathway 
or network (e.g., MetaboAnalyst (17) and IMPaLA (20)). Metabolite an-
notation and pathway enrichment have traditionally been solved as two 
independent problems, where pathway enrichment assumes that the chem-
ical identity of each measured mass is known a priori. In general, pathway 
analysis techniques therefore do not adequately address issues related to 
uncertainty in metabolite annotation. See illustrative example in Fig S1. 
One exception is Mummichog, a set of statistical algorithms that predict 
functional activity directly from measurements considered significant 
when compared to those in a reference sample (21). 
We present a novel inference-based probabilistic approach, Probabilis-
tic modeling for Untargeted Metabolomics Analysis (PUMA), for predict-
ing the likelihood of activity of metabolic pathways within a biological 
sample using Gibbs Sampling, a Monte Carlo Markov Chain (MCMC) 
sampling technique (22), and then deriving probabilistic assignment of 
measurements to candidate chemical identities. Inference has not been ap-
plied prior to such tasks. Further, there are no inference techniques that 
utilize the metabolic model of the underlying the biological sample. Prob-
Metab (23) uses a probabilistic method (24) to assign empirical formulas 
to measured spectra given potential formulas. Another tool constructs a 
generative model to infer the likelihood of a metabolite in the sample and 
the correctness of matching the measurement to a candidate metabolite 
within a spectral database based on measured spectra’s similarity to that 
of the proposed candidate and to other competing spectra in the database 
(25). The competing spectra, however, may not be relevant to the sample.  
Although inference is a well-known machine learning technique, there 
were several challenges in developing PUMA including: 1) identifying a 
suitable generative model that represents the underlying biological pro-
cess, 2) expressing complex relationships using probability distributions, 
3) speeding the inference procedure with complex mathematical margin-
alization and vectorization, 4) identifying best model parameters, and 5) 
validating model against the ground truth. Herein, we describe how 
PUMA addresses such challenges. PUMA is then applied to two data sets 
collected for Chinese Hamster Ovary (CHO) cells (15) and human urinary 
samples (26). Predicted pathway activities are analyzed for biological sig-
nificance and compared against activity predictions obtained through sta-
tistical pathway enrichment analysis. For the CHO cell test case, metabo-
lite annotations obtained using PUMA are compared to those obtained us-
ing methods that utilize the spectral signature to annotate metabolites 
(HMDB (7), METLIN, (6) and BioCAN (15)). For the human urinary 
samples, PUMA annotations are compared to published annotations ob-
tained using spectral databases and experimental validation.  
2 Methods 
2.1 Generative Model 
PUMA first constructs a graphical model (27) that captures the complex 
relation among pathway activities, metabolites, and measurements in a 
single integrated model. The model produces values that are observed 
(measured), as well as hidden variables of interest, which cannot be di-
rectly observed but rather inferred from those values that can be observed. 
In our case, the observations correspond to mass measurements collected 
through untargeted metabolomics. The hidden variables are pathway ac-
tivities and the presence of a metabolite in a biological sample. The gen-
erative model is contrasted against a traditional workflow in Fig S2. 
Our generative model assumes the following biological process: one or 
more pathways are active. An active pathway causes the presence of some 
of its metabolites, which in turn results in observations of masses through 
untargeted metabolomics data collection. The generative model is param-
eterized with prior information, or prior probabilities, about the behavior 
of the biological process. Here, we provide priors on each step in the bio-
logical process: for pathway activities, on pathways generating their me-
tabolites, and metabolites mapping to mass measurements. We assume 
that the biological sample has a metabolic model with 𝐼 pathways, 𝐽 me-
tabolites and 𝐾 unique metabolite masses. A metabolite may have mem-
bership in one or more pathways. A measured mass may be associated 
with one or more masses of the model metabolites. Metabolite masses are 
discretized by 𝐾 bins. Each bin is centered at a unique mass value and 
allows for a mass tolerance of +/-15 ppm.  Each metabolite is assigned to 
a single bin that is centered closest to the metabolite’s mass. A binary vec-
tor 𝑤 has 𝐾	entries and indicates mass observations of metabolites in the 
model. A 1 entry for 𝑤& in vector 𝑤 indicates the observation (measure-
ment) of at least one metabolite in the kth bin while a 0 indicates no obser-
vation for any metabolite in that bin.   
Let 𝑎 = (𝑎*: 𝑖 = 1, … , 𝐼) denote the status of 𝐼	pathways in the biolog-
ical sample, so 𝑎 is a vector of binary random variables, where a value of 
1 indicates that the corresponding pathway is active and 0 indicates inac-
tivity. We assume that the 𝑎* random variables are independent, with a Bernoulli(𝜆) prior: 𝑝(𝑎* = 1) = 𝜆, 𝑖 = 1, … , 𝐼 
For simplicity in defining our model, we assume that 𝜆 is a model param-
eter and set it to a constant.  As an alternative, we can give it a Beta prior.  
Matrix 𝑂 is defined with 𝐼 rows and 𝐽 columns. Each entry 𝑜*=  corre-
sponds to the activeness of metabolite 𝑗 in pathway 𝑖, where a value of 1 
indicates metabolite 𝑗 is active due to pathway 𝑖 and a value of 0 indicates 
that metabolite 𝑗 is not produced by pathway 𝑖. If a metabolite 𝑗 is on a 
pathway 𝑖 , then the metabolite is produced according to the following 
probability.  𝑝?𝑜*= = 1|𝑎* = 1A = 𝜇, 𝑝?𝑜*= = 1|𝑎* = 0A = 0 
Otherwise, 𝑝?𝑜*= = 1|𝑎*A = 0 when 𝑗 is not on 𝑖. For simplicity, we as-
sume that all metabolites are equally likely to be generated with probabil-
ity 𝜇 within an active pathway. Vector 𝑚 collapses the matrix 𝑂 into a bi-
nary vector with 𝐽 elements, indicating the activeness of a metabolite due 
to whichever pathway.  𝑚= = EF𝑜*=* > 0H 
Here [⋅] gives 1 when the condition inside is true or 0 otherwise. 
As not all masses can be captured using the mass spectrometer, its ob-
served accuracy is defined using parameter 𝛾. Let 𝐽& define the group of 
metabolites that have masses in the 𝑘-th bin, then  𝑝?𝑤& = 0N𝑚OPA = (1 − 𝛾)∑ STT∈VP 	. 
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This probability means that every metabolite present in the biological sam-
ple has a chance 𝛾 to be detected. In the case when all metabolites in 𝐽& 
are not observed (∑ 𝑚==∈OP = 0), then mass 𝑘 will not be observed.  The 
detection of a metabolite is independent of the detection of others in the 
sample. No two groups, 𝐽&  and 𝐽&X , intersects because a metabolite has 
only one mass.  The described model is described using the plate repre-
sentation (28) (Fig. 1). The model presents the joint probability distribu-
tion of random variables 𝑎, 𝑜, 𝑚 and 𝑤	defined as: 𝑝(𝑎, 𝑜,𝑚, 𝑤) = 𝑝(𝑎; 𝜆)	𝑝(𝑜|𝑎; 𝜇)	𝑝(𝑚|𝑜)	𝑝(𝑤|𝑚; 𝛾) 
 
 
 
 
2.2 Inference  
Using the probabilistic model, we infer pathway activities and metabo-
lite presence from mass measurements. Specifically, we calculate the fol-
lowing probabilities. For each pathway 𝑖 in the biological sample we cal-
culate 𝑝(𝑎*|𝑤), the posterior probability of pathway 𝑖 being active given 
evidence in mass measurements. PUMA utilizes Gibbs sampling to per-
form Bayesian inference (22) to approximate the posterior probabilities of 
pathway activities conditioned on the measurements. We then infer the 
presence of metabolites by calculating the posterior 𝑝?𝑚=N𝑤A for all 𝑗. We 
use the latter probabilities to rank a candidate set of metabolites for each 
mass measurement, where a candidate set provides one or more suggestion 
of chemical identities that have the same mass, within an error margin, as 
the observed one.  
2.2.1 Inferring pathway activities 
Gibbs sampling is employed to perform Bayesian inference to approx-
imate 𝑝(𝑎|𝑤), the posterior probability of pathway activities conditioned 
on the measurements. Naively sampling random variables a and O is time 
consuming. To speed the Gibbs sampler, we marginalize hidden variables 𝑂. From the Bayesian formula,  𝑝(𝑎|𝑤) = 	𝑝(𝑤|𝑎)𝑝(𝑎)/𝑝(𝑤) 
Gibbs sampling is convenient in that it there is no need to compute the 
denominator 𝑝(𝑤) to draw samples from the posterior 𝑝(𝑎|𝑤). We only 
need to focus the computation of 𝑝(𝑤|𝑎) and 𝑝(𝑎), where the latter was 
already assumed to have a Bernoulli distribution.  Below we show how to 
compute 𝑝(𝑤|𝑎). We point out that 𝑝(𝑤|𝑎) decomposes as follows: 𝑝(𝑤|𝑎) = ∏ 𝑝(𝑤&|𝑎)&   
This is because metabolites in separate 𝐽& groups are independent given 𝑎, so do masses that are computed within these groups.  Then we focus 
on the calculation of 𝑝(𝑤&|𝑎). Let 𝜙=(𝑎) be the probability that at least 
one pathway in the biological sample generates metabolite 𝑚=. That is, 𝜙=(𝑎) = 𝑝?𝑚= = 1N𝑎A. The detailed calculation of 𝜙=(𝑎) is provided in 
the Supplementary File 1, the calculation of 𝜙=(𝑎) is: 𝜙=(𝑎) = 1 − (1 − 𝜇)]T  
with 𝑛=  being the number of active pathways that 𝑗  is on. Probabil-
ity	𝑝(𝑤&|𝑎) is then computed as follows: 𝑝(𝑤&|𝑎) = _ 	1 − 	Πa∈bcd1 − 𝛾𝜙=e								𝑤& = 1	Πa∈bcd1 − 𝛾𝜙=e																	𝑤& = 0 
The expression 1 − 𝛾𝜙=, a number between 0 and 1, represents the likeli-
hood that the mass spectrometer did not measure the activity of metabolite 𝑚=. Combining 𝑝(𝑤&|𝑎) with the Bernoulli prior 𝑝(𝑎),	we have the joint 
probability p(𝑤, 𝑎), which is sufficient for running the sampler and getting 
samples from the posterior. If  𝜆 has a Beta prior, then we will sample a 
and 𝜆 together from 𝑝(𝜆)𝑝(𝑎|𝜆)𝑝(𝑤|𝑎). 
 
2.2.2 Inferring metabolite annotations 
With samples drawn from 𝑝(𝑎|𝑤), we approximate 𝑝?𝑚=N𝑤A, the pos-
terior probability distribution of metabolite 𝑗	being present in the biologi-
cal sample. Instead of running the Gibbs sampling procedure again, we 
use previously collected samples of 𝑎 from 𝑝(𝑎|𝑤) to estimate the proba-
bility 𝑝?𝑚=N𝑤A.  Let 𝑆 = {	𝑎	 ∈ 𝑠𝑎𝑚𝑝𝑙𝑒𝑠	𝑜𝑓	𝑝(𝑎|𝑤)} be a set of samples 
from the distribution 𝑝(𝑎|𝑤) , then  𝑝?𝑚=N𝑤A = Σn𝑝?𝑚=, 𝑎N𝑤A = Σn𝑝?𝑚=N𝑎, 𝑤A𝑝(𝑎|𝑤)≈ 1|𝑆|	Σn∈p	𝑝?𝑚=N𝑎, 𝑤A	
The probability 𝑝?𝑚=N𝑎, 𝑤A has efficient computation. Let 𝑘= denote the 
entry of 𝑤 corresponding to metabolite 𝑗, and let \𝑘= denote other entries 
in 𝑤.  Then:  𝑝?𝑚=N𝑎, 𝑤A = 𝑝?𝑚=, 𝑤N𝑎A𝑝(𝑤|𝑎) = 𝑝 r𝑚=, 𝑤&Ts𝑎t 𝑝 r𝑤\&Ts𝑎t /𝑝(𝑤|𝑎) 
Here we use the fact that 𝑚= and 𝑤&T are independent of other mass obser-
vations when 𝑎 is given. With this relation, we have  
𝑝?𝑚= = 1N𝑎, 𝑤A = 𝑝 r𝑚= = 1,𝑤&Ts𝑎t𝑝 r𝑚= = 1, 𝑤&Ts𝑎t + 	𝑝 r𝑚= = 0, 𝑤&Ts𝑎t 
Here the terms that are constants to 𝑚= are canceled.  
Finally, we can compute 𝑝 r𝑚=,			𝑤&Ts𝑎t by marginalizing over all 𝑚=, 
for 𝑗X ≠ 𝑗 and 𝑗X ∈ 𝐽&: 𝑝 r𝑚=,			𝑤&Ts𝑎t = 	ΣSVP\T	𝑝(𝑚=,𝑚OP\=, 𝑤&T|𝑎)= ΣSVP\T	𝑝 r𝑤&Ts𝑚=	, 𝑚OP\=t 𝑝?𝑚=,𝑚OP\=N𝑎A 
We decompose the above formulation into two terms for managing cal-
culations.  These two terms,  𝑝 r𝑤&s𝑚O&t and 𝑝?𝑚=,𝑚OP\=N𝑎A	are further 
derived and re-expressed in the supplementary material, to yield the fol-
lowing:   
 
 
 
 
 
 
 
 
Fig. 1. Graphical representation of the generative model. To avoid representing all 𝑰 
pathways, 𝑱 metabolites and 𝑲 masses in the graph, we use the ‘plate’ notation and 
draw one representative node per variable and enclosing these variables in a plate 
(rectangular box). The number of instances of each enclosed variable is indicated by 
the fixed constant in the lower right corner of the box. Random variables of the model 
(a, o, m, w) are shown in white circles. The variable m has a deterministic relationship 
with O. The shaded circle, labelled w, represents an observed random variable. 𝝁, 	𝝀, 𝜸 
are parameters to the model.  
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𝑝 r𝑚=, 𝑤&Ts𝑎t
=
⎩⎪⎪
⎪⎪⎪
⎪⎨
⎪⎪⎪
⎪⎪⎪
⎧ ?1 − 𝜙=A  ?1 − 𝛾𝜙=A=∈OP,	== 										𝑚= = 0, 	𝑤&T = 0		?1 − 𝜙=A 1 −  ?1 − 𝛾𝜙=A=∈OP,	== 								𝑚= = 0, 	𝑤&T = 1																			𝜙=(1 − 𝛾)  ?1 − 𝛾𝜙=A=∈OP,	== 													𝑚= = 1, 	𝑤&T = 0	𝜙= 1 − (1 − 𝛾)  ?1 − 𝛾𝜙=A=∈OP,	== 			𝑚= = 1, 	𝑤&T = 1									
 
We use these equations to calculate the probabilities 𝑝 r𝑚= = 1, 𝑤&Ts𝑎t  and 𝑝 r𝑚= = 0, 𝑤&Ts𝑎t . By normalizing the two 
terms to have a sum of 1, we get the posterior of metabolite annotations. 
The derived probabilities are used as a scoring metric to rank a candidate 
set for each mass measurement. Details on the derivation and implemen-
tation of metabolite annotation are provided in Supplementary File 1. 
2.3 Implementation and parameter initialization 
We implemented PUMA using PyMC3 (29), a probabilistic programming 
framework that allows for automatic Bayesian inference on user-defined 
models. In the implementation, we assume that 𝜆 has a Beta prior with 
parameters 𝛼 = 𝛽 = 1. We sample both random variables 𝑎 and 𝜆.  To 
draw samples from a posterior distribution, PyMC3 utilizes a Markov 
Chain Monte Carlo (MCMC) sampling technique (30). The generative 
model was derived from the metabolic model for each of our case studies. 
The observed accuracy of the mass spec, 𝛾, is assumed to be 0.9. Each 
entry in µ is assumed to be 0.5 if metabolite j exists on pathway 𝑖.  T, the 
number of samples to draw from the model, is a variable that can be set in 
PyMC3. The sampler was run multiple times with T values equal to 500, 
1000 and 1500. For all reported runs, increasing the number of drawn sam-
ples did not affect the computed probabilities for pathways activities. Re-
sults are reported for sample sizes of 1000. 
3 Results 
3.1 Model validation  
As there are currently no “ground truth” datasets that can be utilized to 
validate predicted pathway activities, we generated synthetic metabolom-
ics datasets from presumed known biological processes to validate our 
generative models. As central metabolism and network topology is con-
served across many organisms (31), we generated the synthetic datasets 
using a representative organism, the Chinese Hamster Ovary (CHO) cell, 
a popular organism utilized in many biological studies. The metabolic 
model for the CHO cell was culled from KEGG (32), based on unique 
metabolites and pathways for the cricetulus griseus (Chinese hamster) un-
der organism code cge. The model has 86 pathways, 1,534 metabolites, 
and 722 unique mass measurements. 
Several synthetic datasets were generated. A random portion (0.3, 0.5, 
and 0.7) of pathways are assumed active, and a random portion (0.05, 0.10, 
0.15, 0.20, 0.25, 0.50, 0.75) of metabolites within each active pathway are 
generated. For each portion of active pathways and for each portion of 
active metabolites, 100 metabolomics datasets reflecting the masses of the 
active metabolites were generated. The observed accuracy 𝛾 was set to 1. 
We applied PUMA to each dataset and averaged PUMA’s precision, recall 
and accuracy on identifying the presumed active pathways. At a pathway 
activity of 0.3 (Fig. S3A), as we have more observed metabolites, recall 
increases because PUMA has more evidence in terms of observations to 
recover the correct pathway activities.  Precision, PUMA’s ability to label 
true positives correctly, is greater than 0.71, regardless of the active frac-
tion of metabolites. Accuracy improves with increased active metabolites 
due to the corresponding increase in PUMAs ability to identify true posi-
tives.  This trend holds for other assumptions about pathway activities 
(Figs. S4A and S5A). 
We investigate how uncertainty in metabolite annotation impacts infer-
ence regarding pathway activity. Before running PUMA, each mass meas-
urement is attributed to a presumed active metabolite, thus removing an-
notation uncertainty. Results (Fig. S3B, S4B, and S5B) show a similar 
trend to those in Figs. S3A, S4A, and S5A. A similar trend holds when 
each measured mas is randomly assigned a metabolite amongst model me-
tabolites with the same mass as a measured mass (Figs. S3C, S4C, and 
S5C). This result emphasizes that computing pathway activities without 
specific knowledge about metabolite annotation is a profitable approach. 
PUMA can therefore be used to accelerate the process of pathway activity 
analysis by direct use of mass measurements and bypassing metabolite 
annotation using spectral databases.  
We further investigated the robustness of the model to its parameters. 
While prior runs assumed that the probability of observing a metabolite 
due to a particular pathway activity was 0.5, we varied the corresponding 
model parameter 𝜇 to 0.25 and to 0.75 and re-ran PUMA. The results (Fig. 
S7) show that inference is dominated by other aspects of the model and 
that inference is robust to this model parameter.  
 
3.2 Case study 1: Chinese Hamster Ovary (CHO) Cell 
We apply PUMA to LC-MS (liquid-chromatography mass spectrome-
try metabolomics data for CHO cell cultures belonging to a low growth 
cell line (15) (Supplementary Table S1). To increase coverage, data was 
collected separately under three different combinations of liquid chroma-
tography methods and positive or negative ionization modes. When com-
bined, the data provides a more comprehensive characterization of the 
sample in the form of 8,711 measurements. Due to incompleteness of met-
abolic models, there were only 635 metabolites that map to 411 mass 
measurements in the combined dataset. The observed masses for the 
model are used to initialize the observation vector 𝑤 for each dataset.  
3.2.1 Probabilities of pathway activities  
Detailed results for each dataset and for the combined data set is pro-
vided in Supplementary Table S1. A pathway is considered active if  
 
 
 
 
 
 
 
 
 
 
Fig. 2. Probabilities of pathway activities as computed by PUMA vs. enrichment 
ratios for CHO cell. Each data point is marked as either statistically enriched (red) 
or non-statistically enriched (blue) based on a Fisher’s Exact Test p-values of 0.05. 
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𝑝(𝑎*|𝑤) is equal to or greater than 0.5. As mass observations differ from 
one set of measurements to another, the predicted activity differs among 
the datasets. A detailed discussion of the results for the individual datasets 
is provided in Supplementary File S1. The rest of the CHO cell analysis 
provided here is based on the combined dataset. 
Many of the 42 pathways identified active by PUMA are biologically 
relevant.  The biological activity of most pathways such as TCA cycle, 
essential for energy metabolism, Biotin (vitamin B7) metabolism, amino 
acid synthesis, and many others, is expected. However, the activity of 
some pathways including caffeine and drug pathways is biologically un-
likely active in the CHO cell samples. Based on our experiments using the 
synthetic datasets, we expect some PUMA predictions to be false.  
Pathway activities predicted by PUMA are contrasted against pathway 
enrichment ratios (Fig. 2). The enrichment ratio for a particular pathway 
is defined as the ratio of measured masses that map to metabolites within 
the pathway to its size. Pathways are labeled as statistically enriched based 
on statistical significance of their ratios using Fisher’s Exact Test (FET). 
The null hypothesis is that there is no difference between the enrichment 
ratios of pathways in the sample. A p-value equal to or less than 0.05 is 
considered significant. Eight pathways are designated statistically en-
riched. These pathways are Galactose metabolism, Fatty acid degradation, 
Purine metabolism, N-Glycan biosynthesis, Amino sugar and nucleotide 
sugar metabolism, Glycosaminoglycan degradation, Glycerophospholipid 
metabolism, lipoic acid metabolism. Among them, 6 pathways were pre-
dicted by PUMA to be active with probability equal to 1 while the N-Gly-
can biosynthesis pathway had a 0.53 likelihood of being active. Fatty acid 
degradation is predicted to be inactive. There were many pathways that 
had low enrichment ratios and low PUMA-predicted activity.  
While there was consensus in some cases, there were also differences. 
PUMA designates some pathways as active despite low enrichment ratios. 
For example, the enrichment ratios of the TCA cycle, fatty acid biosyn-
thesis, ubiquinone and terpenoid-quinone biosynthesis are 0.15, 0.29, and 
0.13, respectively. Meanwhile, PUMA predicted these pathways active 
with a likelihood of 1. There are three pathways with enrichment ratio 
equal to 0.5. Of them, one pathway, biotin metabolism, is assigned active 
by PUMA with probability 1.0. The biotin metabolism pathway has a 
measured mass that is unique and cannot be generated by other pathways. 
However, the other two pathways, both glycosphingolipid biosynthesis 
pathways, are predicted active with probability less than 0.5 (0.47 and 
0.48). The reason was as follows: the observed mass measurements in the 
glycosphingolipid biosynthesis pathways could be mapped to Galactose 
metabolism and Glycosaminoglycan degradation pathways that are asso-
ciated with a unique measurement that cannot be attributed to any other 
pathway in model (similar to the case of w5 in our illustrative example Fig. 
S1). As the result, the glycosphingolipid biosynthesis pathways were as-
signed probabilities less than 0.5, while the pathways with the unique 
measurements are predicted active with high probability.  
3.2.2 Probabilities of metabolite annotations  
A particular measurement was associated with a model metabolite if its 
mass matched the measured mass within the bin tolerance. Each measure-
ment therefore may be assigned zero, one or more possible annotation. 
Probabilities of each metabolite being present in the sample as inferred by 
PUMA are used to score and rank the putative annotations. Here, only the 
top ranked metabolite(s) for each mass is considered as the PUMA candi-
date set.  
We assess the accuracy of PUMA annotations by comparing the level 
of agreement of PUMA annotations with those using two other techniques, 
spectral database searches and BioCAN (Fig. 3). Spectral signatures col-
lected through untargeted metabolomics were looked up in  METLIN and 
HMDB, and were previously reported (15). The highest scoring metabo-
lites for each measurement in METLIN and in HMDB formed the spectral 
database candidate set. Out of 411 mass measurements, 85 were identified 
as either in HMDB or METLIN. For each measurement, the PUMA can-
didate set was compared against the candidate set identified by HMDB 
and METLIN. The comparison leads to four different scenarios. One sce-
nario is “agreement”, where the PUMA candidate set exactly matches the 
candidate set from HMDB and METLIN. Such agreement occurs in 60 
cases. There are 15 cases of “semi-agreement”, where the candidate set 
from HMDB and METLIN is a subset of the top candidate set obtained 
from PUMA annotation. Three are 10 cases of “disagreement”, where the 
candidate set from METLIN and HMDB does not overlap with the PUMA 
candidate set. In 7 such cases, the candidate metabolite from METLIN and 
HMDB is the second likely putative annotation identified by PUMA. 
These putative annotations, which were not included in the PUMA candi-
date set, had a high activity score and close to that of the metabolite(s) in 
the candidate set. In the remaining three cases, however, the candidate 
metabolite from METLIN and HMDB is assigned a low score by infer-
ence-based annotation workflow, a score far from the one assigned to the 
metabolite in the PUMA candidate set. These three cases are considered 
as genuine disagreement in annotation. Importantly, in the final scenario, 
“Only PUMA”, with 326 cases, there were no matching annotations in 
METLIN and HMDB, reflecting the low coverage of spectral databases. 
PUMA annotations are compared against those obtained using BioCAN 
(15). BioCAN aggregates results from spectral database searches and in 
silico fragmentation tools and estimates the confidence in an annotation 
for a mass measurement not only based on a consensus but also by the 
confidence of presence of metabolites that are connected to the mass meas-
urement through substrate-product relationships. BioCAN annotates 338 
out of 411 mass measurements that are annotated by PUMA. We analyze 
the various scenarios as we did when comparing against spectral database 
annotations. There are 255 cases of agreement, 46 cases of semi-agree-
ment, 37 cases of disagreement, and 73 new annotations by PUMA. The 
disagreements fell into two categories. In 17 out of 37 cases, there was 
disagreement on the top candidate, where PUMA ranked BioCAN’s can-
didate as second best. There were genuine disagreements in 20 cases were 
the annotation by BioCAN was assigned a low score by PUMA.  
In summary, comparing PUMA annotations against those obtained 
through spectral database and BioCAN shows significant levels of agree-
ment. METLIN, HMDB and BioCAN incorporate spectra signatures dur-
ing annotation while PUMA relies solely on pathway organization and 
mass measurements. Importantly, for the CHO cell, PUMA increased an-
notation by 383% over spectral databases and by 21% over BioCAN.  
 
Fig. 3. Metabolite annotations attained with PUMA against those identified by: 
(A) searching spectral databases, HMDB and METLIN, and (B) BioCAN. The 
blue slice in each pie represents “agreement”. The orange and gray slices represent 
“semi-agreement” and “disagreement” respectively. Finally, the yellow slice repre-
sents the number of mass measurements that could only be annotated by PUMA. 
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3.1.3 Evaluation of PUMA in overcoming uncertainty in annotation 
Our synthetic dataset analysis indicated robustness to the uncertainty 
inherent in mapping measurements to metabolites when analyzing path-
way activities using inference. The experiment is repeated using the anno-
tation data for the CHO cell from METLIN and HMDB. For each mass k 
annotated using METLIN or HMDB as metabolite j, matrix 𝜏 is modified. 
Column entries other than 𝜏	*,=  are set to zero, indicating that mass k 
uniquely maps to metabolite	𝑗. Using the updated 𝜏, PUMA calculated 
posteriors for pathway activities. There was a slight change in predicted 
posteriors (average increase of 0.003) compared to those obtained using 
the original 𝜏 matrix. The change however does not alter posterior proba-
bilities sufficiently to modify the list of active pathways. We repeated the 
analysis but incorporated the annotation data available from BioCAN in-
stead of that obtained through spectral databases. The change in 𝜏 caused 
a slight change in predicted posteriors (an average of 0. 001 per pathway) 
compared to those obtained using the original 𝜏 matrix. The one signifi-
cant change was for pathway Phenylalanine metabolism where pathway 
activity changed from 0.03 to 1.0. The Phenylalanine metabolism pathway 
is responsible for producing Tyrosine. this finding shows that substantial 
additional annotations, as provided in the form of added annotations by 
BioCAN over the use of spectral databases, are required to inform infer-
ence in regard to pathway activities. Importantly, the results are in agree-
ment with those for the synthetic dataset: annotating metabolites first has 
limited impact on the accuracy of computing pathway activities.  
 
3.3 Case study 2: human urinary sample 
We apply PUMA to untargeted metabolomics datasets collected for hu-
man urinary samples analyzed by Roux et al. (26). Detailed annotations 
are provided for 384 measurements. The metabolic model for the urinary 
sample was derived from BioCyc (33). The model had 275 pathways, 716 
metabolites, and 565 unique masses.  Only 123 out of the Roux et al. meas-
ured masses matched to those in the model.   
3.3.1 Probabilities of pathway activities  
PUMA designated 41 pathways as active in human urinary sample 
(Supplementary Table S1). We investigate how inference results com-
pare with pathway enrichment ratios (Fig. 4). Of the 41 pathways desig-
nated to be active using PUMA, six pathways (tRNA charging, 4-hydrox-
yproline degradation I, histidine degradation VI, lysine degradation II, pu-
rine ribonucleosides degradation to ribose-1-phosphate, nicotine degrada-
tion III) are statistically enriched. As in the CHO cell cases, there were 
cases of agreement and disagreement. There are several pathways were 
PUMA predicts low activity, while enrichment assumes a high enrichment 
ratio, including alanine biosynthesis II, glutamate degradation II, aspartate 
biosynthesis, arginine degradation VI and alanine degradation III. The 
probabilities for these pathways are 0.26, 0.22, 0.17, 0.31 and 0.25, re-
spectively, while the corresponding enrichment ratios are 1.0, 0.57, 0.75, 
0.6 and 1.0. Many measurements assigned to these pathways, however, 
are not unique as they can generated due to activity of other pathways.  
3.3.2 Probabilities of metabolite annotations 
The PUMA probabilities for each metabolite being present in the sam-
ple are used to score and rank metabolites. Only the top ranked metabo-
lite(s) for each mass are considered as the PUMA candidate set. We com-
pared our annotation against those provided by Roux et al. (26) (Fig. 5). 
These annotations were either identified by matching at least two of their 
physicochemical parameters to those in a reference standard or annotated 
through spectral database lookups (HMDB). Some measurements were 
annotated as isomers, without identifying the precise chemical molecular 
identity. Of the 108 measured masses that matched to metabolites in the 
model, there were 85 cases of “agreement”, where PUMA predictions 
matched the Roux et al. annotations. There were 23 cases of “clarifica-
tion”, where PUMA provided a specific chemical annotation while Roux 
et al annotated the measurement as an isomer. There was one case of “dis-
agreement”, where a Roux et al. annotation was predicted not present by 
PUMA.  Finally, there were 14 “model incompleteness issue” cases where 
Roux et al assigned the measurement a chemical identity that was not in 
the model, indicating that PUMA provides the best match within the scope 
of model metabolites.  We expect that more comprehensive metabolic 
model could address such issues.  
 
3.4 Model complexity and runtimes 
The time and space complexity in sampling the model is O(𝑇 x 𝑃	x	𝐹). 
The runtime for drawing 1000 samples for pathway activity prediction and 
metabolite annotation for the CHO cell dataset were 231 and 0.5 seconds, 
respectively. The corresponding runtimes for the Human Urinary case 
study were 280 and 0.4 seconds, respectively. The runs were performed 
on a Dell PowerEdge R815 server with 64 cores (4x AMD Opteron 6380 
processors) and 128Gb of RAM, running at 2.5GHz. 
4 Conclusion 
We presented in this paper PUMA, a probabilistic approach to interpret 
mass measurements collected through untargeted metabolomics. Because 
it is based on inference, PUMA allows drawing stronger conclusions about 
 
 
 
 
 
 
 
 
 
 
Fig. 4. Probabilities of pathway activities as computed by PUMA vs. enrichment 
ratios for the human urine sample. Each data point is marked as either statistically 
enriched (red) or non-statistically enriched (blue) based on a Fisher’s Exact Test p-
values of 0.05. 
 
 
Fig. 5. Metabolite annotations attained with PUMA against those identified by 
Roux et al. The blue slice represents “agreement”. The orange slice represents “clar-
ification”. The gray slice represents “disagreement” and the yellow slice represents 
“model incompleteness issue”. 
PUMA 
activities of the biological sample under study by folding in what is al-
ready known about the sample. In doing so, levels of uncertainty in map-
ping measurements to metabolites and pathways are significantly reduced, 
and a clearer view of the likelihood of pathway activity levels and metab-
olite annotation emerges.  
PUMA provides significant contributions in advancing both pathway 
analysis and metabolite annotation. Pathways identified by PUMA as 
highly active are ones with essential biological roles in the samples under 
study. Further, PUMA offers a perspective on pathway activity that is dis-
tinctly different from that offered by statistical enrichment approaches. 
PUMA identifies pathways that have a high likelihood of being active but 
have statistically low enrichment ratios, and pathways with low activity 
probabilities yet with statistically high enrichment ratios. Because infer-
ence reduces the uncertainty in mapping measurements to chemical iden-
tities, PUMA was able to infer pathway activities without the additional 
burden of metabolite annotation. For the CHO cell tests case, PUMA was 
able to infer pathway activity levels similar to those identified with addi-
tional annotation information from other tools. In terms of advancing an-
notation, PUMA results had high agreement to annotations using spectral 
database lookups and BioCAN. This high level of agreement occurs de-
spite the fact that PUMA does not utilize additional information in form 
of spectra signatures, as employed other techniques. Importantly, PUMA 
suggested annotations for measurements that were not previously anno-
tated by other techniques. In the case of the CHO cell test case, PUMA 
increased the percentage of mass annotation by 383% over spectral 
lookups and by 21% over BioCAN. For the human urine test case, PUMA 
suggested 23 new identities that were previously only identified as isomers 
and 85 out of 86 possible matched manually curated annotations. 
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